ReviewJournal of computer-aided molecular design2026
A survey of transformer and LLM-based architectures, workflows, and systems in drug discovery.
Review in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery has greatly benefited from the recent progress in Artificial Intelligence (AI). Numerous tasks within pharmaceutical research and development are being formulated as classification, regression, generation, or sequence-to-sequence problems, and tackled via AI systems that can learn from data, making the process of discovery and screening faster and more efficient. Two of the greatest breakthroughs in AI have arguably been the advent of transformers and Large Language Models (LLMs). With their parallel processing capabilities, their ability to detect dependencies and interactions in sequence data, and the vast knowledge stored in their millions or billions of parameters, transformers and LLMs are successful, highly popular additions to the computational drug discovery arsenal. This work provides an extensive overview of transformer-based architectures and workflows utilized in drug discovery. The conducted analysis focuses on the types of transformers and LLMs currently in use, as well as the systems and workflows that integrate them. Research findings indicate the transformer architecture's exceptional flexibility and adaptability, which support its implementation across diverse configurations and systems. This versatility positions it as a transformative model with the promising potential to revolutionize drug discovery and drive significant scientific breakthroughs.
Indexed as
Identifiers
42611136What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.